Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial
- 31 August 2008
- journal article
- research article
- Published by Elsevier BV in Bone
- Vol. 43 (2), 222-229
- https://doi.org/10.1016/j.bone.2008.04.007
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Two-Year Treatment With Denosumab (AMG 162) in a Randomized Phase 2 Study of Postmenopausal Women With Low BMDJournal of Bone and Mineral Research, 2007
- Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized miceBone, 2004
- Ten Years' Experience with Alendronate for Osteoporosis in Postmenopausal WomenThe New England Journal of Medicine, 2004
- Rapid Loss of Hip Fracture Protection After Estrogen Cessation: Evidence From the National Osteoporosis Risk AssessmentObstetrics & Gynecology, 2004
- Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) studyMenopause, 2003
- Sustained Antiresorptive Effects After a Single Treatment With Human Recombinant Osteoprotegerin (OPG): A Pharmacodynamic and Pharmacokinetic Analysis in RatsJournal of Bone and Mineral Research, 2003
- Osteoclast differentiation and activationNature, 2003
- Bone mass, bone strength, muscle–bone interactions, osteopenias and osteoporosesMechanisms of Ageing and Development, 2003
- Osteoprotegerin, an endogenous antiosteoclast factor for protecting bone in rheumatoid arthritisArthritis & Rheumatism, 2002
- Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 1998